BR112012009436A2 - método, dispositivo e kit para determinar a quantidade de polipeptídeo de neurotoxina a (bont/a) - Google Patents

método, dispositivo e kit para determinar a quantidade de polipeptídeo de neurotoxina a (bont/a)

Info

Publication number
BR112012009436A2
BR112012009436A2 BR112012009436A BR112012009436A BR112012009436A2 BR 112012009436 A2 BR112012009436 A2 BR 112012009436A2 BR 112012009436 A BR112012009436 A BR 112012009436A BR 112012009436 A BR112012009436 A BR 112012009436A BR 112012009436 A2 BR112012009436 A2 BR 112012009436A2
Authority
BR
Brazil
Prior art keywords
amount
bont
determining
kit
unprocessed
Prior art date
Application number
BR112012009436A
Other languages
English (en)
Portuguese (pt)
Inventor
Brünn Cornelia
V Taylor Harold
Eisele Karl-Heinz
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41466928&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012009436(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of BR112012009436A2 publication Critical patent/BR112012009436A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96402—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals
    • G01N2333/96405—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general
    • G01N2333/96408—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general with EC number
    • G01N2333/96419—Metalloendopeptidases (3.4.24)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
BR112012009436A 2009-10-21 2010-10-18 método, dispositivo e kit para determinar a quantidade de polipeptídeo de neurotoxina a (bont/a) BR112012009436A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27945309P 2009-10-21 2009-10-21
EP09173612 2009-10-21
PCT/EP2010/065618 WO2011048044A1 (en) 2009-10-21 2010-10-18 System for determining unprocessed and partially processed neurotoxin type a

Publications (1)

Publication Number Publication Date
BR112012009436A2 true BR112012009436A2 (pt) 2017-02-21

Family

ID=41466928

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012009436A BR112012009436A2 (pt) 2009-10-21 2010-10-18 método, dispositivo e kit para determinar a quantidade de polipeptídeo de neurotoxina a (bont/a)

Country Status (15)

Country Link
US (2) US8841080B2 (enExample)
EP (1) EP2491384B1 (enExample)
JP (1) JP5709877B2 (enExample)
KR (1) KR101788340B1 (enExample)
CN (1) CN102597769B (enExample)
AU (1) AU2010309932B2 (enExample)
BR (1) BR112012009436A2 (enExample)
CA (1) CA2773478C (enExample)
ES (1) ES2449303T3 (enExample)
IL (1) IL218455A (enExample)
IN (1) IN2012DN01954A (enExample)
MX (1) MX2012004454A (enExample)
PT (1) PT2491384E (enExample)
RU (1) RU2545825C9 (enExample)
WO (1) WO2011048044A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1786459B1 (en) * 2004-07-26 2014-02-12 Merz Pharma GmbH & Co. KGaA Therapeutic composition whit a botulinum neurotoxin
RU2549463C1 (ru) * 2013-12-03 2015-04-27 Федеральное бюджетное учреждение науки Государственный научный центр прикладной микробиологии и биотехнологии (ФБУН ГНЦ ПМБ) Способ определения ботулинического нейротоксина типа а на основе иммунодетекции, сопряженной с полимеразной цепной реакцией
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000067700A2 (en) 1999-05-12 2000-11-16 United States Army Medical Research & Materiel Cmd Recombinant vaccine against botulinum neurotoxin
WO1999037326A1 (en) * 1998-01-26 1999-07-29 University Of Massachusetts Biologically active hemagglutinin from type a clostridium botulinum and methods of use
US6667158B1 (en) * 1998-12-17 2003-12-23 The United States Of America As Represented By The Secretary Of The Army Antibodies against type a botulinum neurotoxin
US20080171347A1 (en) * 2003-04-11 2008-07-17 Atassi M Zouhair Determining and reducing immunoresistance to botulinum toxin therapy using botulinum toxin a peptides
FR2869908B1 (fr) * 2004-05-05 2006-07-28 Pharmaleads Substrat peptidique reconnu par la toxine botulique de type a, bont/a et son utilisation pour detecter et/ou doser ladite toxine ou des inhibiteurs de son activite
CN100575363C (zh) * 2007-03-07 2009-12-30 中国人民解放军军事医学科学院微生物流行病研究所 人源抗a型肉毒神经毒素基因工程抗体及其制备方法与用途
US7732579B2 (en) * 2007-06-13 2010-06-08 The United States Of America As Represented By The Secretary Of Agriculture High-affinity monoclonal antibodies for botulinum toxin type A
BRPI1008885B1 (pt) * 2009-02-19 2021-09-28 Merz Pharma Gmbh & Co. Kgaa Método para obter uma solução purificada de polipeptídeos de neurotoxina processados e composição
CN101503472B (zh) * 2009-03-17 2011-08-10 中国人民解放军军事医学科学院生物工程研究所 抗a型肉毒毒素的人源性中和抗体及其应用

Also Published As

Publication number Publication date
KR101788340B1 (ko) 2017-10-19
CA2773478A1 (en) 2011-04-28
US9213026B2 (en) 2015-12-15
EP2491384A1 (en) 2012-08-29
RU2545825C2 (ru) 2015-04-10
EP2491384B1 (en) 2013-12-04
IL218455A0 (en) 2012-04-30
JP2013508701A (ja) 2013-03-07
PT2491384E (pt) 2014-02-21
US20120214182A1 (en) 2012-08-23
RU2012120572A (ru) 2013-11-27
CN102597769B (zh) 2014-11-05
RU2545825C9 (ru) 2015-06-20
AU2010309932A1 (en) 2012-04-05
MX2012004454A (es) 2012-05-22
AU2010309932B2 (en) 2015-04-16
US20140349322A1 (en) 2014-11-27
KR20120102639A (ko) 2012-09-18
ES2449303T3 (es) 2014-03-19
IL218455A (en) 2015-10-29
US8841080B2 (en) 2014-09-23
JP5709877B2 (ja) 2015-04-30
CN102597769A (zh) 2012-07-18
HK1173493A1 (zh) 2013-05-16
WO2011048044A1 (en) 2011-04-28
CA2773478C (en) 2018-07-17
IN2012DN01954A (enExample) 2015-08-21

Similar Documents

Publication Publication Date Title
BR112013033488A2 (pt) marcadores biológicos de micro-rna indicativo da doença de alzheimer
BR112015022141A2 (pt) Método de quantificação de eficiência de capeamento de mrna, kit e método de fabricação de mrna
BR112014030607A2 (pt) métodos e aparelhos para controlar e/ou monitorar um atuador pneumático
AU2018260845A1 (en) Evaluation and treatment of bradykinin-mediated disorders
BR112012018294A2 (pt) método para detectar dióxido de carbono e sulfeto de hidrogênio em um ambiente de furo abaixo, e, aparelho de ferramenta de furo abaixop para detectar o dióxido de carbono e o sulfeto de hidrogênio.
BR112013028539A2 (pt) método e aparelho para controlar um veículo, e, produto de programa de computador para controlar um veículo
WO2013081461A3 (en) Methods and kits for determining protein-bound biomarkers
DE602006008310D1 (de) Biomarker für eierstockkrebs: mit ctap3 verwandte proteine
BRPI1007374A8 (pt) Método e aparelho para monitoramento da condição de estado de válvulas
WO2013092952A3 (de) Verfahren zur selektiven quantifizierung von a-beta-aggregaten
DE602007011476D1 (de) Diagnostik-biomolekül(e)
CL2012001353A1 (es) Método de detección de un evento de soja en una muestra basada en poner en contacto dicha muestra con un polinucleótido específico para el evento aad-12 pdab4468-0416; método para determinar cigocidad de dicho evento en una planta de soja y kit de detección de adn.
BR112016028494A2 (pt) método e aparelho para processo de flotação em espuma usando medidas ópticas
BR112014009223A8 (pt) método para o diagnóstico da doença de niemann-pick
DK2118666T3 (da) Fremgangsmåde til normalisering af koncentrationen af analytter i en urinprøve
SG10201907690TA (en) Device and method for detecting target molecules
BRPI0803089A2 (pt) ensaio de proteìnas
MX2009008525A (es) La determinacion cuantitativa de risedronato en orina mediante spe-lc-ms-ms.
HRP20160554T1 (hr) Analitički postupak za molekule fab i fab'
GB201119585D0 (en) Assay
IN2012DN01954A (enExample)
BRPI0816437B8 (pt) polipeptídeos purificados e métodos para a detecção de ehrlichia chaffeensis em uma amostra teste
BR112014008311A2 (pt) método de prognóstico para diabetes
GB0608377D0 (en) Reagents and methods
BR112018015532A2 (pt) métodos para o diagnóstico de pré-eclâmpsia, para avaliar a gravidade da pré-eclâmpsia, e para o monitoramento pré-eclâmpsia, usos de biomarcador, kit adaptado para a realização do método e dispositivo adaptado para diagnosticar se uma paciente sofre de pré-eclâmpsia

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]